Posted by Michael Wonder on 16 Oct 2023
Santhera receives positive CHMP opinion recommending approval of Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy
13 October 2023 - Agamree could become the first drug fully approved by the EMA for the treatment of patients with Duchenne muscular dystrophy.
Santhera Pharmaceuticals announces that the CHMP adopted a positive opinion in favour of approval of Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy patients aged 4 years and older.
